---
layout: default
title: Aluminum Hydroxide Magnesium Hydroxide
parent: 僅模型預測 (L5)
nav_order: 276
evidence_level: L5
indication_count: 0
---

# Aluminum Hydroxide Magnesium Hydroxide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

這份 Evidence Pack 的 `predicted_indications` 為空陣列，屬於特殊情境（無預測結果可展示）。以下按規則省略空白章節，僅輸出有實質內容的部分。

---

# Aluminum Hydroxide + Magnesium Hydroxide: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Aluminum hydroxide combined with magnesium hydroxide is a well-known antacid combination used for acid-related gastrointestinal conditions.
The TxGNN pipeline returned **no predicted indications** for this drug, and the Evidence Pack contains **no market authorization records** and **no safety data**, making a repurposing assessment impossible at this stage.
This report documents the data gaps and recommends remediation steps before re-evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assessable (no predictions) |
| Market Status | Not marketed (0 authorizations found) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why the Pipeline Returned No Predictions

The pipeline was unable to produce repurposing candidates for this drug for the following likely reasons:

**DrugBank ID is missing.** The Evidence Pack records `drugbank_id: null`, meaning the TxGNN knowledge graph could not link this drug to a graph node. Without a valid DrugBank node, the knowledge graph traversal and deep-learning scoring steps cannot run, producing an empty `predicted_indications` array.

**The drug name is a compound string.** The query used `"ALUMINUM HYDROXIDE; MAGNESIUM HYDROXIDE"` as a single token. Most mapping pipelines expect individual INN names. The semicolon-delimited format may have caused the normalizer to fail to match either component to a DrugBank entry.

**Market data absence may be an artefact.** Aluminum hydroxide/magnesium hydroxide combination products (e.g., Maalox, Mylanta) are widely sold OTC in most markets. Zero authorizations is likely a retrieval miss — possibly because OTC products use different registration pathways — rather than genuine absence from the market.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predictions were generated because the DrugBank mapping failed, making the knowledge-graph and deep-learning steps inoperable. There is no candidate indication to evaluate, and all safety fields are flagged as data gaps.

**To proceed, the following is needed:**

1. **Resolve DG002 (High) — Identify DrugBank IDs for both components**
   - Aluminum hydroxide: DB01592 (DrugBank)
   - Magnesium hydroxide: DB14021 (DrugBank)
   - Update the pipeline to pass each component separately, then merge predictions.

2. **Resolve DG001 (Blocking) — Obtain package insert warnings and contraindications**
   - Source: Regulatory authority official website
   - Method: Download and parse the package insert PDF.

3. **Verify market registration status**
   - Confirm whether OTC registrations are captured in the current data source; if not, extend the query to OTC/over-the-counter databases.

4. **Re-run TxGNN pipeline**
   - After DrugBank IDs are confirmed, re-run `run_kg_prediction.py` and `txgnn_model.py` for each individual component (aluminum hydroxide and magnesium hydroxide), then generate the combined Evidence Pack.

5. **Consider evaluating components individually**
   - Literature and clinical trial evidence for antacid repurposing (e.g., aluminum hydroxide in hyperphosphatemia, magnesium hydroxide as a laxative) exists and may surface meaningful TxGNN candidates once properly mapped.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

